Currently Viewing:
Newsroom
Currently Reading
PASI Scores Can Indicate Who Will, Will Not Respond to Tildrakizumab for Psoriasis, Study Says
September 30, 2019 – AJMC Staff
Early Levels of Ustekinumab May Predict Longer-term Response in Patients With Psoriasis
September 21, 2019 – Laura Joszt
Researchers Examine Metabolic Syndrome Links to Inflammatory Skin Disorder Lichen Planus
September 20, 2019 – AJMC Staff
Case Report Describes Patient With Psoriasis Who Developed IBD After Secukinumab
September 11, 2019 – Allison Inserro
Could Understanding HLA-C Lead to Precision Therapy in Psoriatic Arthritis?
September 09, 2019 – Kelly Davio
More Research Needed About Link Between Psoriasis, Alcohol
September 05, 2019 – Allison Inserro
Screen Patients With Psoriasis for Obstructive Sleep Apnea, Researchers Say
September 03, 2019 – AJMC Staff
5 Things About Psoriasis and Its Complications
August 30, 2019 – Allison Inserro
Celgene Sells Psoriasis Drug Otezla to Amgen for $13.4 Billion
August 26, 2019 – Allison Inserro

PASI Scores Can Indicate Who Will, Will Not Respond to Tildrakizumab for Psoriasis, Study Says

AJMC Staff
Knowing who may respond to tildrakizumab early on may help providers and patients decide whether to continue with treatment, the researchers said.
A recent post-hoc analysis of tildrakizumab—approved last year by the FDA and marketed under the name Ilumya for patients with moderate-to-severe psoriasis—shows that looking at Psoriasis Area and Severity Index (PASI) improvement scores early in treatment can indicate who is most likely to respond to treatment.

Tildrakizumab is a biologic that blocks interleukin-23 (IL-23) and is given by injection every 12 weeks.

The results come from an analysis of the 2 phase 3 trial data sets (reSURFACE 1 and 2) that led to tildrakizumab’s approval last year. PASI scores were separated in 5 groups, 0–49, 50–74, 75–89, 90–99, and 100, meaning the percentage of skin cleared of lesions. Nonresponders, or those who achieved PASI scores of under 50% by week 28, can be identified as early as week 8, the study reported.

Patients who responded extremely well—those who reached PASI scores of 90% or more by week 28—could be identified as early as week 4, with about a 50% improvement.

The authors wrote that “it is of potential interest to physicians, patients and payers to understand how different groups of patients have better or worse responses and how patients respond over time using different efficacy parameters.” Using the results, patients and providers can decide whether to continue tildrakizumab therapy or not by week 12 or 16, or before the third dose, the authors said.

Patients treated with tildrakizumab 100 mg or 200 mg from baseline to week 28 were pooled from the 2 studies and classified into the 5 mutually exclusive week-28 PASI improvement groups for each dose. Only 8.3% and 4% of patients with psoriasis treated with tildrakizumab 100 mg and 200 mg, respectively, failed to achieve at least 50% PASI improvement at week 28. As early as week 8, these patients had a lower percentage of PASI improvement.

Among patients achieving PASI scores of 90% or more at week 28, tildrakizumab 100 mg and 200 mg were associated with rapid PASI improvement from baseline (approximately 50%) by week 4. Patients with a higher PASI response demonstrated better quality of life improvement.

Among patients achieving PASI greater than 50% at week 28 who continued the same dose of tildrakizumab to week 52, mean PASI improvement was maintained or improved over time. Similar results were observed for both doses.

In addition, tildrakizumab had similar efficacy in patients with and without prior use of biologics.

Reference

Blauvelt A, Sofen H, Papp K, et al. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials [published online August 13, 2019]. J Eur Acad Dermatol Venereol. doi: 10.1111/jdv.15862.

Related Articles

Researcher Excited About Future of Psoriasis Treatment
Treating RA With Anti-TNF Agents Is Linked With a Higher Risk of Incident Psoriasis
US Patients With Psoriasis Face 2-Fold Mortality Risk, Study Finds
5 Things About Psoriasis and Its Complications
Case Report Describes Patient With Psoriasis Who Developed IBD After Secukinumab
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up